Terms: = Leukemia AND BRD4, O60885, 23476, ENSG00000141867, HUNKI, CAP, MCAP AND Prognosis
26 results:
1. m
Zhao Y; Zhou Y; Qian Y; Wei W; Lin X; Mao S; Sun J; Jin J
Clin Transl Med; 2024 Apr; 14(4):e1628. PubMed ID: 38572589
[TBL] [Abstract] [Full Text] [Related]
2. IκB kinase-α coordinates brd4 and JAK/STAT signaling to subvert DNA damage-based anticancer therapy.
Pecharromán I; Solé L; Álvarez-Villanueva D; Lobo-Jarne T; Alonso-Marañón J; Bertran J; Guillén Y; Montoto Á; Martínez-Iniesta M; García-Hernández V; Giménez G; Salazar R; Santos C; Garrido M; Borràs E; Sabidó E; Bonfill-Teixidor E; Iurlaro R; Seoane J; Villanueva A; Iglesias M; Bigas A; Espinosa L
EMBO J; 2023 Nov; 42(21):e114719. PubMed ID: 37737566
[TBL] [Abstract] [Full Text] [Related]
3. Retinoic acid and proteotoxic stress induce AML cell death overcoming stromal cell protection.
Liccardo F; Śniegocka M; Tito C; Iaiza A; Ottone T; Divona M; Travaglini S; Mattei M; Cicconi R; Miglietta S; Familiari G; Nottola SA; Petrozza V; Tamagnone L; Voso MT; Masciarelli S; Fazi F
J Exp Clin Cancer Res; 2023 Aug; 42(1):223. PubMed ID: 37653435
[TBL] [Abstract] [Full Text] [Related]
4. Targeting MYC in combination with epigenetic regulators induces synergistic anti-leukemic effects in MLLr leukemia and simultaneously improves immunity.
Fitzel R; Secker-Grob KA; Keppeler H; Korkmaz F; Schairer R; Erkner E; Schneidawind D; Lengerke C; Hentrich T; Schulze-Hentrich JM; Schneidawind C
Neoplasia; 2023 Jul; 41():100902. PubMed ID: 37148657
[TBL] [Abstract] [Full Text] [Related]
5. MicroRNA profiling of paediatric AML with
Leoncini PP; Vitullo P; Reddel S; Tocco V; Paganelli V; Stocchi F; Mariggiò E; Massa M; Nigita G; Veneziano D; Fadda P; Scarpa M; Pigazzi M; Bertaina A; Rota R; Pagliara D; Merli P
Oncol Rep; 2022 Dec; 48(6):. PubMed ID: 36321792
[TBL] [Abstract] [Full Text] [Related]
6. Overexpression of Bromodomain and Extraterminal Domain is Associated with Progression, Metastasis and Unfavorable Outcomes: Highlighting Prognostic and Therapeutic Value of the BET Protein Family in Gastric Cancer.
Fard SS; Kouchaki S; Salimian Z; Sotoudeh M; Mousavi SA; Alimoghaddam K; Ghaffari SH
Anticancer Agents Med Chem; 2023; 23(7):794-806. PubMed ID: 36284375
[TBL] [Abstract] [Full Text] [Related]
7. brd4 Inhibitor GNE-987 Exerts Anticancer Effects by Targeting Super-Enhancer-Related Gene LYL1 in Acute Myeloid leukemia.
Sang X; Zhang Y; Fang F; Gao L; Tao Y; Li X; Zhang Z; Wang J; Tian Y; Li Z; Yao D; Wu Y; Chu X; Zhang K; Ma L; Lu L; Chen Y; Yu J; Zhuo R; Wu S; Zhang Z; Pan J; Hu S
J Immunol Res; 2022; 2022():7912484. PubMed ID: 35958877
[TBL] [Abstract] [Full Text] [Related]
8. A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid leukemia Cells.
Zhang K; Gao L; Wang J; Chu X; Zhang Z; Zhang Y; Fang F; Tao Y; Li X; Tian Y; Li Z; Sang X; Ma L; Lu L; Chen Y; Yu J; Zhuo R; Wu S; Pan J; Hu S
Pathol Oncol Res; 2022; 28():1610447. PubMed ID: 35832114
[TBL] [Abstract] [Full Text] [Related]
9. The CDK4/6-UCHL5-brd4 axis confers resistance to BET inhibitors in MLL-rearranged leukemia cells by suppressing brd4 protein degradation.
Amari K; Sasagawa S; Imayoshi N; Toda Y; Hosogi S; Imamura T; Ashihara E
Biochem Biophys Res Commun; 2022 Jan; 588():147-153. PubMed ID: 34954522
[TBL] [Abstract] [Full Text] [Related]
10. Small-Molecule Inhibitors Targeting eIF4A in leukemia.
Jia X; Zhou H
Curr Protein Pept Sci; 2021; 22(7):559-566. PubMed ID: 34042032
[TBL] [Abstract] [Full Text] [Related]
11. Targeting RUNX1 in acute myeloid leukemia: preclinical innovations and therapeutic implications.
Gonzales F; Barthélémy A; Peyrouze P; Fenwarth L; Preudhomme C; Duployez N; Cheok MH
Expert Opin Ther Targets; 2021 Apr; 25(4):299-309. PubMed ID: 33906574
[No Abstract] [Full Text] [Related]
12. Bromodomain protein brd4 is an epigenetic activator of B7-H6 expression in acute myeloid leukemia.
Baragaño Raneros A; Rodriguez RM; Bernardo Flórez A; Palomo P; Colado E; Minguela A; Suárez Álvarez B; López-Larrea C
Oncoimmunology; 2021 Mar; 10(1):1897294. PubMed ID: 33796404
[TBL] [Abstract] [Full Text] [Related]
13. LEDGF/p75-mediated chemoresistance of mixed-lineage leukemia involves cell survival pathways and super enhancer activators.
Canella A; Van Belle S; Brouns T; Nigita G; Carlon MS; Christ F; Debyser Z
Cancer Gene Ther; 2022 Feb; 29(2):133-140. PubMed ID: 33795806
[TBL] [Abstract] [Full Text] [Related]
14. KAT7 is a genetic vulnerability of acute myeloid leukemias driven by MLL rearrangements.
Au YZ; Gu M; De Braekeleer E; Gozdecka M; Aspris D; Tarumoto Y; Cooper J; Yu J; Ong SH; Chen X; Tzelepis K; Huntly BJP; Vassiliou G; Yusa K
Leukemia; 2021 Apr; 35(4):1012-1022. PubMed ID: 32764680
[TBL] [Abstract] [Full Text] [Related]
15. A comprehensive review of genetic alterations and molecular targeted therapies for the implementation of personalized medicine in acute myeloid leukemia.
Kirtonia A; Pandya G; Sethi G; Pandey AK; Das BC; Garg M
J Mol Med (Berl); 2020 Aug; 98(8):1069-1091. PubMed ID: 32620999
[TBL] [Abstract] [Full Text] [Related]
16. Molecular profiling of adult acute myeloid and lymphoid leukemia in a major referral center in Lebanon: a 10-year experience report and review of the literature.
Assaf N; El-Cheikh J; Bazarbachi A; Salem Z; Farra C; Chakhachiro Z; Nassif S; Zaatari G; Mahfouz R
Mol Biol Rep; 2019 Apr; 46(2):2003-2011. PubMed ID: 30701458
[TBL] [Abstract] [Full Text] [Related]
17. Antileukemic Efficacy of BET Inhibitor in a Preclinical Mouse Model of MLL-AF4
Bardini M; Trentin L; Rizzo F; Vieri M; Savino AM; Garrido Castro P; Fazio G; Van Roon EHJ; Kerstjens M; Smithers N; Prinjha RK; Te Kronnie G; Basso G; Stam RW; Pieters R; Biondi A; Cazzaniga G
Mol Cancer Ther; 2018 Aug; 17(8):1705-1716. PubMed ID: 29748211
[No Abstract] [Full Text] [Related]
18. Evaluation of Testing of Acute leukemia Samples: Survey Result From the College of American Pathologists.
George TI; Tworek JA; Thomas NE; Fatheree LA; Souers RJ; Nakhleh RE; Arber DA
Arch Pathol Lab Med; 2017 Aug; 141(8):1101-1106. PubMed ID: 28537804
[TBL] [Abstract] [Full Text] [Related]
19. Functional interdependence of brd4 and DOT1L in MLL leukemia.
Gilan O; Lam EY; Becher I; Lugo D; Cannizzaro E; Joberty G; Ward A; Wiese M; Fong CY; Ftouni S; Tyler D; Stanley K; MacPherson L; Weng CF; Chan YC; Ghisi M; Smil D; Carpenter C; Brown P; Garton N; Blewitt ME; Bannister AJ; Kouzarides T; Huntly BJ; Johnstone RW; Drewes G; Dawson SJ; Arrowsmith CH; Grandi P; Prinjha RK; Dawson MA
Nat Struct Mol Biol; 2016 Jul; 23(7):673-81. PubMed ID: 27294782
[TBL] [Abstract] [Full Text] [Related]
20. c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells.
Roderick JE; Tesell J; Shultz LD; Brehm MA; Greiner DL; Harris MH; Silverman LB; Sallan SE; Gutierrez A; Look AT; Qi J; Bradner JE; Kelliher MA
Blood; 2014 Feb; 123(7):1040-50. PubMed ID: 24394663
[TBL] [Abstract] [Full Text] [Related]
[Next]
